GLI1 and esophageal cancer: Previous studies have reported aberrant activation of HH/GLI signaling in esophageal cancer, which can be caused by a number of factors [24–26] including genetic alterations of individual pathway components, such as PTCH or SMO mutations and GLI1/2 amplification [27].